VamsiKKotaMD

Oncology • Augusta, GA

Assistant Professor, Medicine, Medical College of Georgia at Georgia Health Sciences University

Join to view full profile

Dr. Kota is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kota's full profile

Already have an account?

Office
1120 15th St
Augusta, GA 30912
Phone+1 706-721-3813

Fax+1 706-721-1459
Is this information wrong?

Summary

Dr. Vamsi Kota is an oncologist in Augusta, GA. He received his medical degree from Armed Forces Medical College Pune and has been in practice 14 years. He is experienced in hematologic oncology, multiple myeloma, and leukemia.

Education & Training

Medical College of GeorgiaFellowship, Hematology and Medical Oncology, 2008 - 2011
Medical College of GeorgiaResidency, Internal Medicine, 2004 - 2007
ArMed Forces Medical College PuneClass of 2003

Certifications & Licensure

GA State Medical License 2007 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia Start of enrollment: 2016 Oct 01
Terminated
Phase 2
Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia Start of enrollment: 2017 Aug 03
Active, not recruiting
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
Active, not recruiting
Phase 2
The EMPATHY Pilot Study Start of enrollment: 2019 Nov 01
Completed
Not Applicable
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Start of enrollment: 2021 Jan 25
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

HSR24-147: Non-Optimal Treatment in Early-Line Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Tyrosine Kinase Inhibitors (TKI): A Claims...
David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav, Vamsi Kota> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eig...
Yasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Talha Badar, Emily M Geramita, Vamsi K Kota, Alok Swaroop, Peter Doukas, D...> ;American Journal of Hematology. 2024 Apr 1
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: resul...
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Patel, Jan P Bewersdorf, Adam S ...> ;Blood Cancer Journal. 2024 Feb 20
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Altman, J., Zuckerman, T., Koprivnikar, J., McCloskey, J., Kota, V., Keng, M., Frankfurt, O., Abaza, Y., Bixby, D., Emadi, A., Burch, M., Bhatnagar, B., Luger, S., Per...> ;Blood Advances. 2023 Dec 26
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
Winn, A., Deininger, M., Moore, J., Shah, N., Flynn, K., Atallah, E., Cortes, J., Kota, V., Larson, R., Mauro, M., Oehler, V., Pinilla-Ibarz, J., Radich, J., Thompson, J.> ;JAMA Network Open. 2023 Dec 1
Industry's role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials.
Tahsin Anwar, Sean Malhotra, Mohammad A H Mian, Tahiya Anwar, Vamsi Kota, Mahran Shoukier> ;Hematology. 2023 Dec 1
2 citations
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
Fabio Efficace, Francesco Cottone, Betina Yanez, Vamsi Kota, Fausto Castagnetti, Giovanni Caocci, Massimiliano Bonifacio, Andrea Patriarca, Isabella Capodanno, Maria C...> ;Cancer. 2024 Jan 1
Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers.
Pankaj Ahluwalia, Ashutosh Vashisht, Harmanpreet Singh, Nikhil Shri Sahajpal, Ashis K Mondal, Kimya Jones, Jaspreet Farmaha, Ryan Bloomquist, Caroline Marie Carlock, D...> ;Journal of Medical Virology. 2023 Sep 1
1 citations
Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis.
Olivia Kronick, Xinyu Chen, Nidhi Mehra, Armon Varmeziar, Rachel Fisher, David Kartchner, Vamsi Kota, Cassie S Mitchell> ;Cancers. 2023 Aug 31
Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation.
Nikhil Shri Sahajpal, Ashis K Mondal, Ashutosh Vashisht, Harmanpreet Singh, Andy Wing Chun Pang, Daniel Saul, Omar Nivin, Benjamin Hilton, Barbara R DuPont, Vamsi Kota...> ;Genes. 2023 Aug 25
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study.
Jorge E Cortes, Jeff H Lipton, Vamsi Kota, Fausto Castagnetti, Sarit Assouline, Tim H Brümmendorf, Eric Leip, Andrea Viqueira, Carlo Gambacorti-Passerini> ;Haematologica. 2023 Dec 1
3 citations
Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers.
Nikhil Shri Sahajpal, Ashis K Mondal, Harmanpreet Singh, Ashutosh Vashisht, Sudha Ananth, Daniel Saul, Alex R Hastie, Benjamin Hilton, Barbara R DuPont, Natasha M Sava...> ;Cancers. 2023 Jun 16
1 citations
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-...
Pau Montesinos, Vamsi Kota, Joseph Brandwein, Pierre Bousset, Rebecca J Benner, Erik Vandendries, Ying Chen, Mary Frances McMullin> ;Cancer Chemotherapy and Pharmacology. 2023 May 1
Immune Factors Drive Expression of SARS-CoV-2 Receptor Genes Amid Sexual Disparity.
Ashutosh Vashisht, Pankaj Ahluwalia, Ashis K Mondal, Harmanpreet Singh, Nikhil S Sahajpal, Sadanand Fulzele, Vamsi Kota, Gagandeep K Gahlay, Ravindra Kolhe> ;Viruses. 2023 Feb 28
10 citations
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Cons...
Talha Badar, Ehab Atallah, Rory Shallis, Antoine N Saliba, Anand Patel, Jan P Bewersdorf, Justin Grenet, Maximilian Stahl, Adam Duvall, Madelyn Burkart, Neil Palmisian...> ;Leukemia. 2023 Apr 1
2 citations
Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting.
Anda Gershon, Esprit Ma, Tao Xu, Melissa Montez, Kiran Naqvi, Grace Ku, Wendy Wei-Han Cheng, Evelyn M Flahavan, Vamsi Kota, Daniel R Greenwald> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 May 1
2 citations
Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes.
Vamsi Kota, Augustina Ogbonnaya, Eileen Farrelly, Bridgette Kanz Schroader, Aditya Raju, Fjoralba Kristo, Mehul Dalal> ;Future Oncology. 2022 Nov 1
20 citations
Clinical Validation and Diagnostic Utility of Optical Genome Mapping for Enhanced Cytogenomic Analysis of Hematological Neoplasms.
Nikhil S Sahajpal, Ashis K Mondal, Tatiana Tvrdik, Jennifer Hauenstein, Huidong Shi, Kristin K Deeb, Debra Saxe, Alex R Hastie, Alka Chaubey, Natasha M Savage, Vamsi K...> ;The Journal of Molecular Diagnostics. 2022 Dec 1
Economic Impact of Transformation to Acute Myeloid Leukemia Among Actively Managed Patients with Higher-Risk Myelodysplastic Syndromes in the United States.
Vamsi Kota, Augustina Ogbonnaya, Eileen Farrelly, Bridgette Kanz Schroader, Aditya Raju, Fjoralba Kristo, Mehul Dalal> ;Advances in Therapy. 2023 Apr 1
7 citations
Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Nidhi Mehra, Armon Varmeziar, Xinyu Chen, Olivia Kronick, Rachel Fisher, Vamsi Kota, Cassie S Mitchell> ;Cancers. 2022 Sep 26
14 citations
PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2.
Viviana Simon, Vamsi Kota, Ryan F Bloomquist, Hannah B Hanley, David Forgacs, Savita Pahwa, Suresh Pallikkuth, Loren G Miller, Joanna Schaenman, Michael R Yeaman, Davi...> ;Msphere. 2022 Jun 29
2 citations
Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment.
Ajibade Ashaye, Caitlin Thomas, Mehul Dalal, Vamsi Kota, Nicolas Krucien, Maria Sae-Hau, Elisa Weiss, Scott Campbell, Kevin Marsh> ;Future Oncology. 2022 Jun 1
36 citations
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
Tim H Brümmendorf, Jorge E Cortes, Dragana Milojkovic, Carlo Gambacorti-Passerini, Richard E Clark, Philipp le Coutre, Valentin Garcia-Gutierrez, Charles Chuah, Vamsi ...> ;Leukemia. 2022 Jul 1
4 citations
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
Kathryn E Flynn, Ehab Atallah, Li Lin, Neil P Shah, Richard T Silver, Richard A Larson, Javier Panilla-Ibarz, James E Thompson, Vivian G Oehler, Jerald P Radich, Vamsi...> ;Haematologica. 2022 Nov 1
9 citations
Clinical validation of a multiplex PCR-based detection assay using saliva or nasopharyngeal samples for SARS-Cov-2, influenza A and B.
Nikhil S Sahajpal, Ashis K Mondal, Sudha Ananth, Allan Njau, Kimya Jones, Pankaj Ahluwalia, Eesha Oza, Ted M Ross, Vamsi Kota, Arvind Kothandaraman, Sadanand Fulzele, ...> ;Scientific Reports. 2022 Mar 3
Join now to see all

Abstracts/Posters

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integr...
Vamsi Kota, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates
Vamsi Kota, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Help Desk for Oncologists Treating People with a Rare Leukemia Pays Big DividendsFebruary 2nd, 2023
'It Was Miraculous:' Cancer Patient First to Get New Immunotherapy at AU Health SystemMay 27th, 2021
Cassie Mitchell: Competing for Team USA in the Paralympic GamesSeptember 7th, 2016
Join now to see all